Tularemia vaccine candidate: Emergex announces 1st step in development
by Press Release from Outbreak News Today on (#4WF76)
Emergex Vaccines Holding Limited, a biotechnology company developing population-based synthetic disease prophylaxis set-point vaccines in the field of infectious diseases, today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis. Specifically, Emergex has successfully generated a 1st generation human specific MHC-Class I ["]
The post Tularemia vaccine candidate: Emergex announces 1st step in development appeared first on Outbreak News Today.